# Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

> **NCT06219915** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Michigan** · enrollment: 13 (actual)

## Conditions studied

- Parkinsonian Signs in Older Persons

## Interventions

- **DRUG:** Carbidopa 25 mg
- **DRUG:** Carbidopa-Levodopa 25/100 mg
- **DRUG:** Placebo 1
- **DRUG:** Placebo 2

## Key facts

- **NCT ID:** NCT06219915
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-15
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06219915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06219915, "Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06219915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*